Mohammad Reza Haghshenas

Dr. Mohammad Reza Haghshenas

orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 August 2012 in Lung Cancer
Verified
Journal Article
Closed access
NENasrolla Erfani
Nasrolla Erfani
SMShayesteh Mofakhami Mehrabadi
Shayesteh Mofakhami Mehrabadi
MGMohammad Ali Ghayumi
Mohammad Ali Ghayumi
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
ZMZahra Mojtahedi
Zahra Mojtahedi
DADavar Amani
Davar Amani

1 April 2013 in Journal of Molecular Structure
Verified
Journal Article
Closed access
MKMarzieh Khandani
Marzieh Khandani
TSTahereh Sedaghat
Tahereh Sedaghat
NENasrolla Erfani
Nasrolla Erfani
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
HKHamid Reza Khavasi
Hamid Reza Khavasi

1 March 2014 in Immunology Letters
Verified
Journal Article
Closed access
ZFZahra Faghih
Zahra Faghih
NENasrolla Erfani
Nasrolla Erfani
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
ASAkbar Safaei
Akbar Safaei
ATAbdol-Rasoul Talei
Abdol-Rasoul Talei
AGAbbas Ghaderi
Abbas Ghaderi

27 May 2009 in Journal of Gastroenterology and Hepatology
Verified
Journal Article
Closed access
PDF file
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
SHSeyed Vahid Hosseini
Seyed Vahid Hosseini
MMMahmoud Mahmoudi
Mahmoud Mahmoudi
MSMehdi Saberi‐Firozi
Mehdi Saberi‐Firozi
SFShirin Farjadian
Shirin Farjadian
AGAbbas Ghaderi
Abbas Ghaderi

27 November 2010 in Molecular Biology Reports
Verified
Journal Article
Closed access
PDF file
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
KVKhalil Khashei Varnamkhasti
Khalil Khashei Varnamkhasti
ATAbdolrasoul Talei
Abdolrasoul Talei
AGAbbas Ghaderi
Abbas Ghaderi
NENasrolla Erfani
Nasrolla Erfani

1 January 2009 in Acta Oncologica
Verified
Journal Article
Closed access
AFAkbar Farjadfar
Akbar Farjadfar
ZMZahra Mojtahedi
Zahra Mojtahedi
MGMohammad Ali Ghayumi
Mohammad Ali Ghayumi
NENasrolla Erfani
Nasrolla Erfani
MHMohammad Reza Haghshenas
Mohammad Reza Haghshenas
AGAbbas Ghaderi
Abbas Ghaderi
Interleukin-18 (IL-18) is a multifunctional cytokine that augments IFN-gamma production and affects tumor immune response. In the present case-control study, we tested whether IL-18 promoter polymorphism contributes to lung cancer susceptibility in Iranian patients. The study groups were 73 patients with lung cancer, including 53 with squamous carcinoma (SC) and 20 with small cell lung carcinoma (SCLC), and 97 healthy regional aged-matched individuals. The frequency of IL-18 promoter single nucleotide polymorphisms (SNPs) at positions -656 (G/T), -607 (C/A), and -137 (G/C) was determined by polymerase chain reaction analyses. There were significant differences in the IL-18 -607 allele and genotype distributions between the 73 lung cancer patients and controls. A significantly higher A allele frequency at position -607, which is associated with lower IL-18 production, was observed in lung cancer patients (48.6% vs. 35%; OR = 1.75; 95% CI 1.13-2.72). Also, patients with the -607 CA and the AA genotypes had a 2.60-fold (95% CI 1.26-5.36) and 3.15-fold (95% CI 1.16-8.55) increase in risk of lung cancer. Subdivision of the patients according to histological type revealed that SC was significantly associated with IL-18 -607 SNPs. Although the percentages of -607 alleles and genotypes in SCLC patients were similar to the results in SC patients, the differences compared to control individuals did not reach statistical significance. Analysis with Arlequin software identified eight haplotypes from three SNPs analyzed here. The distributions of IL-18 gene haplotypes were not significantly different between patients and controls after Bonferroni correction. This is the first report to investigate the association between IL-18 polymorphism and lung cancer. Our results suggest that IL-18 polymorphism contributes to the lung cancer risk, particularly among SC patients. Further studies with larger numbers of patients are required to determine the possible association between IL-18 polymorphisms and different histological types of lung cancer.